Cargando…

Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study

SIMPLE SUMMARY: Idelalisib, the first-in-class phosphatidylinositol 3-kinase inhibitor, approved by the Italian Medicines Agency for the treatment of relapsed/refractory follicular lymphoma patients, showed high antitumor activity with an acceptable safety profile in a phase II registration trial. A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Casadei, Beatrice, Argnani, Lisa, Broccoli, Alessandro, Patti, Caterina, Stefani, Piero Maria, Cuneo, Antonio, Margiotta Casaluci, Gloria, Visco, Carlo, Gini, Guido, Pane, Fabrizio, D’Alò, Francesco, Luzi, Debora, Cantonetti, Maria, Pozzi, Samantha, Musuraca, Gerardo, Rosignoli, Chiara, Arcari, Annalisa, Kovalchuk, Sofya, Tani, Monica, Tisi, Maria Chiara, Petrini, Mario, Stefoni, Vittorio, Zinzani, Pier Luigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833724/ https://www.ncbi.nlm.nih.gov/pubmed/35158922 http://dx.doi.org/10.3390/cancers14030654

Ejemplares similares

A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report
por: Broccoli, Alessandro, et al.
Publicado: (2018)

Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience
por: Broccoli, Alessandro, et al.
Publicado: (2021)

BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia
por: Broccoli, Alessandro, et al.
Publicado: (2019)

First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi
por: Broccoli, A., et al.
Publicado: (2019)

High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience
por: Derenzini, Enrico, et al.
Publicado: (2015)

The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients
por: Broccoli, Alessandro, et al.
Publicado: (2017)

ABCL-298 Diffuse Large B-Cell Lymphoma During the Covid-19 Pandemic in Two Tertiary Centers: The Israeli/Italian Study
por: Giladi, Odil, et al.
Publicado: (2022)

Poster: ABCL-298 Diffuse Large B-Cell Lymphoma During the Covid-19 Pandemic in Two Tertiary Centers: The Israeli/Italian Study
por: Giladi, Odil, et al.
Publicado: (2022)

Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia
por: Broccoli, Alessandro, et al.
Publicado: (2023)

BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience
por: Stefoni, Vittorio, et al.
Publicado: (2022)

Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results
por: Stefoni, V, et al.
Publicado: (2016)

Effectiveness of chemotherapy after anti‐PD‐1 blockade failure for relapsed and refractory Hodgkin lymphoma
por: Casadei, Beatrice, et al.
Publicado: (2020)

Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients
por: Casadei, Beatrice, et al.
Publicado: (2020)

Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia
por: Broccoli, Alessandro, et al.
Publicado: (2021)

Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy
por: Argnani, Lisa, et al.
Publicado: (2022)

90‐yttrium‐ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high‐risk follicular lymphoma: updated long‐term results after a median follow‐up of 7 years
por: Casadei, Beatrice, et al.
Publicado: (2016)

Management of central nervous system relapse in a young patient affected by primary mediastinal large B‐cell lymphoma: A case report
por: Marangon, Miriam, et al.
Publicado: (2020)

Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization
por: Hohaus, Stefan, et al.
Publicado: (2018)

Cotrimoxazole Prophylaxis Specifically Selects for Cotrimoxazole Resistance in Streptococcus mutans and Streptococcus sobrinus with Varied Polymorphisms in the Target Genes folA and folP
por: William, Buwembo, et al.
Publicado: (2012)

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
por: Khan, Maliha, et al.
Publicado: (2014)

Idelalisib: a rare cause of enterocolitis
por: Balagoni, Harika, et al.
Publicado: (2016)

PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
por: Tarantelli, Chiara, et al.
Publicado: (2021)

Vitamin D deficiency and supplementation in patients with aggressive B‐cell lymphomas treated with immunochemotherapy
por: Hohaus, Stefan, et al.
Publicado: (2017)

An unusual case of Idelalisib‐related pneumonitis with severe respiratory failure
por: Sousa, Domingos, et al.
Publicado: (2020)

Primary Pancreatic Lymphoma in a Patient with Maturity Onset Diabetes of the Young Type 3
por: Bozzoli, Valentina, et al.
Publicado: (2012)

Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience
por: Casadei, Beatrice, et al.
Publicado: (2021)

FolVps9, a Guanine Nucleotide Exchange Factor for FolVps21, Is Essential for Fungal Development and Pathogenicity in Fusarium oxysporum f. sp. lycopersici
por: Li, Bing, et al.
Publicado: (2019)

CNS Prophylaxis: How Far Is Routine Practice From the Guidelines? Focus on a Nationwide Survey by the Fondazione Italiana Linfomi (FIL)
por: Gini, Guido, et al.
Publicado: (2021)

Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper
por: Cuneo, Antonio, et al.
Publicado: (2018)

Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS
por: Stefoni, Vittorio, et al.
Publicado: (2020)

FolX from Pseudomonas aeruginosa is octameric in both crystal and solution
por: Gabrielsen, Mads, et al.
Publicado: (2012)

Subversion of Metabolic Wasting as the Mechanism for folM-Linked Sulfamethoxazole Resistance
por: Minato, Yusuke, et al.
Publicado: (2017)

Mutations of folC cause increased susceptibility to sulfamethoxazole in Mycobacterium tuberculosis
por: Wang, Ruiqi, et al.
Publicado: (2021)

FILE OF LIFE: OLDER ADULT PERSPECTIVES AND SUGGESTIONS TO INCREASE FOL USAGE
por: Dandrea, Kaye, et al.
Publicado: (2022)

Crystal structure of idelalisib tert-butanol monosolvate dihydrate
por: Nerdinger, Sven, et al.
Publicado: (2019)

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
por: Sharman, Jeff P., et al.
Publicado: (2019)

Environmental Occurrence and Predicted Pharmacological Risk to Freshwater Fish of over 200 Neuroactive Pharmaceuticals in Widespread Use
por: Sumpter, John P., et al.
Publicado: (2022)

Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses
por: Alflen, Astrid, et al.
Publicado: (2018)

Rapid and complete response to idelalisib in a case of Richter syndrome
por: Bagacean, Cristina, et al.
Publicado: (2019)

Idelalisib induces PUMA-dependent apoptosis in colon cancer cells
por: Yang, Shida, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kdgtd6f7bpfrutk92jj115hev7